Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [OV5398PDX RNAseq]
We performed RNA sequencing on tumors harvested from OV5398 (ovarian) PDX treated for 40-50 days with either control vehicle (PEG), 100 mg/kg BID INX-315 or 200 mg/kg QD INX315. Overall design: Mice with OV5398 (ovarian) PDX tumours were treated with either control vehicle (PEG), 200 mg/kg QD INX-315 or 100 mg/kg BID INX-315. cells were collected 2 hours following final treatment. 3-5 replicates were collected per group.